{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:37:55Z","timestamp":1759847875219},"reference-count":41,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.24009","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T22:14:56Z","timestamp":1719440096000},"page":"107-118","source":"Crossref","is-referenced-by-count":1,"title":["Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy"],"prefix":"10.3960","volume":"64","author":[{"given":"Yu","family":"Yagi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kanemasa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Ishimine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mano","family":"Mino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Ohigashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Okuya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Shimizuguchi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384: 842-858.","DOI":"10.1056\/NEJMra2027612"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125: 22-32.","DOI":"10.1182\/blood-2014-05-577189"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tilly H, Morschhauser F, Sehn LH <i>et al.<\/i> Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386: 351-363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Philip T, Guglielmi C, Hagenbeek A <i>et al.<\/i> Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995; 333: 1540-1545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Gisselbrecht C, Glass B, Mounier N <i>et al.<\/i> Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184-4190.","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 van Imhoff GW, McMillan A, Matasar MJ <i>et al.<\/i> Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol. 2017; 35: 544-551.","DOI":"10.1200\/JCO.2016.69.0198"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Crump M, Kuruvilla J, Couban S <i>et al.<\/i> Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014; 32: 3490-3496.","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Schuster SJ, Bishop MR, Tam CS <i>et al.<\/i> Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019; 380: 45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Neelapu SS, Locke FL, Bartlett NL <i>et al.<\/i> Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377: 2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Abramson JS, Palomba ML, Gordon LI <i>et al.<\/i> Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396: 839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Nastoupil LJ, Jain MD, Feng L <i>et al.<\/i> Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38: 3119-3128.","DOI":"10.1200\/JCO.19.02104"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Bethge WA, Martus P, Schmitt M <i>et al.<\/i> GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022; 140: 349-358.","DOI":"10.1182\/blood.2021015209"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kuhnl A, Roddie C, Kirkwood AA <i>et al.<\/i> A national service for delivering CD19 CAR\u2010Tin large B\u2010cell lymphoma - The UK real\u2010world experience. Br J Haematol. 2022; 198: 492-502.","DOI":"10.1111\/bjh.18209"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kwon M, Iacoboni G, Reguera JL <i>et al.<\/i> Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023; 108: 110-121.","DOI":"10.3324\/haematol.2022.280805"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Bachy E, Le Gouill S, Di Blasi R <i>et al.<\/i> A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022; 28: 2145-2154.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 B\u00fccklein V, Perez A, Rejeski K <i>et al.<\/i> Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed\/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. Hemasphere. 2023; 7: e907.","DOI":"10.1097\/HS9.0000000000000907"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Locke FL, Miklos DB, Jacobson CA <i>et al.<\/i> Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022; 386: 640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Bishop MR, Dickinson M, Purtill D <i>et al.<\/i> Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022; 386: 629-639.","DOI":"10.1056\/NEJMoa2116596"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kamdar M, Solomon SR, Arnason J <i>et al.<\/i> Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399: 2294-2308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Farooq U, Maurer MJ, Thompson CA <i>et al.<\/i> Clinical heterogeneity of diffuse large B cell lymphoma following failure of front\u2010line immunochemotherapy. Br J Haematol. 2017; 179: 50-60.","DOI":"10.1111\/bjh.14813"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Ayers EC, Li S, Medeiros LJ <i>et al.<\/i> Outcomes in patients with aggressive B\u2010cell non\u2010Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020; 126: 293-303.","DOI":"10.1002\/cncr.32526"},{"key":"22","unstructured":"22 Swerdlow SH, Campo E, Harris NL, <i>et al.<\/i> WHO classification of tumours of haematopoietic and lymphoid tissues. rev. 4th ed ed: International Agency for Research on Cancer; 2017."},{"key":"23","unstructured":"23 Swerdlow SH, Campo E, Harris NL, <i>et al.<\/i> WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed ed: International Agency for Research on Cancer; 2008."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Hans CP, Weisenburger DD, Greiner TC <i>et al.<\/i> Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 . A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329: 987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8: 551-561.","DOI":"10.1002\/sim.4780080504"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2020; 55: 675-680.","DOI":"10.1038\/s41409-019-0679-x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Hamadani M, Hari PN, Zhang Y <i>et al.<\/i> Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20: 1729-1736.","DOI":"10.1016\/j.bbmt.2014.06.036"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Armand P, Welch S, Kim HT <i>et al.<\/i> Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013; 160: 608-617.","DOI":"10.1111\/bjh.12176"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M. Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy. Transplant Cell Ther. 2021; 27: 55.e1-55.e7.","DOI":"10.1016\/j.bbmt.2020.09.004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Sauter CS, Matasar MJ, Meikle J <i>et al.<\/i> Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015; 125: 2579-2581.","DOI":"10.1182\/blood-2014-10-606939"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Shadman M, Pasquini M, Ahn KW <i>et al.<\/i> Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022; 139: 1330-1339.","DOI":"10.1182\/blood.2021013289"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Shah NN, Ahn KW, Litovich C <i>et al.<\/i> Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021; 137: 1416-1423.","DOI":"10.1182\/blood.2020007939"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Ngu HS, Hilton LK, Rodrigo JA <i>et al.<\/i> Diffuse large B-cell lymphoma (DLBCL) patients with late relapses who are transplant-eligible have excellent outcomes and may represent unique biology. Blood. 2021; 138: 2499.","DOI":"10.1182\/blood-2021-149049"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 von Matt S, Bacher U, Banz Y <i>et al.<\/i> Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment. Mediterr J Hematol Infect Dis. 2023; 15: e2023025.","DOI":"10.4084\/MJHID.2023.025"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Vercellino L, Di Blasi R, Kanoun S <i>et al.<\/i> Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4: 5607-5615.","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Roddie C, Neill L, Osborne W <i>et al.<\/i> Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023; 7: 2872-2883.","DOI":"10.1182\/bloodadvances.2022009019"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Schuster SJ, Tam CS, Borchmann P <i>et al.<\/i> Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22: 1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Abramson JS, Solomon SR, Arnason J <i>et al.<\/i> Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023; 141: 1675-1684.","DOI":"10.1182\/blood.2022018730"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Westin JR, Oluwole OO, Kersten MJ <i>et al.<\/i> Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023; 389: 148-157.","DOI":"10.1056\/NEJMoa2301665"},{"key":"41","unstructured":"41 Neelapu SS, Jacobson CA, Ghobadi A <i>et al.<\/i> Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large\u00a0B-cell lymphoma. Blood. 2023; 141: 2307-2315."}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/2\/64_24009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T04:51:59Z","timestamp":1719636719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/2\/64_24009\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24009","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"24009"}}